IL17A and psoriasis vulgaris: Monoclonal antibodies, particularly interleukin-17 (IL-17) inhibitors such as secukinumab and ixekizumab, have become cornerstone treatments for managing recalcitrant moderate to severe plaque psoriasis [1-3].